600789 鲁抗医药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.0362.48710.4817.0654.157
总资产报酬率 ROA (%)0.5351.1744.4092.8091.668
投入资产回报率 ROIC (%)0.6401.4055.2953.4252.023

边际利润分析
销售毛利率 (%)21.31422.07523.96324.65522.191
营业利润率 (%)4.0912.7856.9984.4272.647
息税前利润/营业总收入 (%)5.4983.7867.8215.5254.061
净利润/营业总收入 (%)3.4971.9416.5514.1782.546

收益指标分析
经营活动净收益/利润总额(%)113.81291.76661.33087.575110.645
价值变动净收益/利润总额(%)-1.808-3.283-1.743-2.639-4.351
营业外收支净额/利润总额(%)0.9090.394-0.5270.3080.881

偿债能力分析
流动比率 (X)1.5331.4571.3491.0370.850
速动比率 (X)1.1371.0900.8640.6370.491
资产负债率 (%)46.24347.61255.35757.49659.816
带息债务/全部投入资本 (%)33.81135.59744.55747.42249.281
股东权益/带息债务 (%)185.541171.215115.868104.10496.474
股东权益/负债合计 (%)113.069107.05977.79771.36264.301
利息保障倍数 (X)4.0143.8239.0975.0962.919

营运能力分析
应收账款周转天数 (天)47.60052.72450.30843.65740.512
存货周转天数 (天)88.316109.428109.766112.194110.639